Zobrazeno 1 - 1
of 1
pro vyhledávání: '"M Z Nakadar"'
Autor:
P Canales-Herrerias, M Uzzan, A Seki, R S Czepielewski, B Verstockt, A Dunn, D Dai, H M Ko, G C Furtado, M Tokuyama, M Tankelevich, H Meringer, F Cossarini, D Jha, J D Paulsen, M Z Nakadar, J Wong, K Sharma, A Rosenstein, T Dawson, H Singh, J Lim, S A Lira, V Yajnik, A Reboldi, F Petralia, S Vermeire, A D Polydorides, G J Randolph, J F Colombel, S Mehandru
Publikováno v:
Journal of Crohn's and Colitis. 17:i227-i228
Background Vedolizumab (VDZ) is a frontline drug for Ulcerative colitis (UC) and Crohn’s disease (CD) that targets integrin α4β7, a gut-homing receptor. Despite significant use, the mechanism(s) of action (MOA) of VDZ remain unclear. Methods Peri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26d697badb28167b5997ab0e82d09c38
https://doi.org/10.1093/ecco-jcc/jjac190.0191
https://doi.org/10.1093/ecco-jcc/jjac190.0191
